Last reviewed · How we verify

Disorder of blood vessel — Treatment Landscape & Competitive Intelligence

Disorder of blood vessel (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Disorder of blood vessel, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Vasodil TOLAZOLINE Novartis tolazoline Alpha-2A adrenergic receptor 1948-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Disorder of blood vessel
  2. Novartis · 1 drug in Disorder of blood vessel

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Disorder of blood vessel:

Cite this brief

Drug Landscape (2026). Disorder of blood vessel — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/disorder-of-blood-vessel. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing